



UTILIZATION MANAGEMENT MEDICAL POLICY

POLICY: Ophthalmology – Luxturna Utilization Management Medical Policy

- Luxturna® (voretigene neparvovec-rzyl subretinal injection – Spark Therapeutics)

REVIEW DATE: 02/23/2022

OVERVIEW

Luxturna, an adeno-associated virus vector-based gene therapy, is indicated for the treatment of patients with confirmed **biallelic human retinal pigment epithelial 65 kDa protein (RPE65) mutation-associated retinal dystrophy**.¹ Patients must have viable retinal cells as determined by the treating physician(s).

Luxturna is made up of a live, non-replicating adeno-associated virus serotype 2 which has been genetically modified to express the human RPE65 gene.¹ Luxturna is designed to deliver a normal copy of the gene encoding RPE65 to cells of the retina in patients with reduced or absent levels of biologically active RPE65. Treatment with Luxturna is not recommended for patients younger than 12 months of age, because the retinal cells are still undergoing cell proliferation, and Luxturna would potentially be diluted or lost during cell proliferation. The safety and effectiveness of Luxturna have not been established in geriatric patients. Clinical studies of Luxturna for this indication did not include patients ≥ 65 years of age.

Disease Overview

Inherited retinal dystrophies are a broad group of genetic retinal disorders that are associated with progressive visual dysfunction.² RPE65 mutation-associated retinal dystrophy is associated with at least 125 discrete gene mutations and affects 1,000 to 2,000 patients in the US.^{2,3} Mutations in the RPE65 gene lead to reduced or absent levels of RPE65 isomerohydrolase activity.¹ The absence of RPE65 leads to the accumulation of toxic precursors, damage to RPE-producing cells, and, over time, damage to photoreceptors, progressing to near total blindness in most patients. The retinal anatomy is preserved for a relatively long period, and supplying the missing enzyme can result in restoration of the visual cycle and improvement in vision.³

Dosing Information

The recommended dose of Luxturna for each eye is 1.5×10^{11} vector genomes (vg) administered once per eye by subretinal injection.¹ After completing a vitrectomy (removal of the vitreous gel that fills the eye cavity) and under direct visualization, a small amount of Luxturna is injected slowly until an initial subretinal bleb is observed; the remaining volume is then injected slowly until the total 0.3 mL is delivered. Luxturna should be injected into each eye on separate days within a close interval, but no fewer than 6 days apart.

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Luxturna. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Because of the specialized skills required for evaluation and diagnosis of patients treated with Luxturna as well as the specialized training required for administration of Luxturna, approval requires Luxturna to be administered by a retinal specialist. All approvals are provided for one injection per eye. Note: A 1-month (30 days) approval duration is applied to allow for the one-time treatment of both eyes. All reviews (approvals and denials) will be forwarded to the Medical Director for evaluation.

Documentation: Documentation is required for use of Luxturna as noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts, and/or other information.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Luxturna is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Biallelic Human Retinal Pigment Epithelial 65 kDa Protein (RPE65) Mutation-Associated Retinal Dystrophy.** Approve for a one-time treatment course (i.e., a total of two injections, one injection in each eye) if the patient meets the following criteria (A, B, C, D, and E):

- A) Patient has a genetically confirmed diagnosis of biallelic RPE65 mutation-associated retinal dystrophy **[documentation required]**; AND
- B) Patient is ≥ 12 months of age and < 65 years of age **[documentation required]**; AND
- C) Luxturna is administered by a retinal specialist **[documentation required]**; AND
- D) Patient must have viable retinal cells as determined by the treating physician **[documentation required]**; AND
- E) Patient is not receiving retreatment of eye(s) previously treated with Luxturna **[documentation required]**.

Dosing. Approve the following dosing regimen (A and B):

- A) One 1.5×10^{11} vector genomes (vg) injection administered by subretinal injection into each eye; AND
- B) The doses for the first eye and the second eye are separated by at least 6 days (i.e., injection of the second eye occurs 6 or more days after injection of the first eye).

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Luxturna is not recommended in the following situations:

- 1. **Retreatment of previously treated eye(s).** Luxturna is for one-time use in each eye. Repeat dosing in previously treated eye(s) is not approvable.
- 2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

- 1. Luxturna[®] subretinal injection [prescribing information]. Philadelphia, PA: Spark Therapeutics; December 2019.
- 2. FDA news release. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. Published on: December 19, 2017. Page last updated: March 16, 2018. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss>. Accessed on February 21, 2022.
- 3. Spark Therapeutics. Luxturna[™] (voretigene neparvovec). FDA Advisory Committee Briefing Document. Meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee. Meeting date: October 12, 2017. Available at: <https://www.fda.gov/media/108385/download>. Accessed on February 21, 2022.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	02/17/2021
Selected Revision	Biallelic Human Retinal Pigment Epithelial 65 kDa Protein (RPE65) Mutation-Associated Retinal Dystrophy: “According to the prescribing physician” was removed from the criterion requiring the patient to have a genetically confirmed diagnosis of biallelic RPE65 mutation-associated retinal dystrophy. The criterion for patient age for treatment was changed to include an upper age limit of “< 65 years of age”.	06/09/2021
Selected Revision	Policy Statement: The statement “All reviews (approvals and denials) will be forwarded to the Medical Director for evaluation” was added.	09/08/2021
Selected Revision	Biallelic Human Retinal Pigment Epithelial 65 kDa Protein (RPE65) Mutation-Associated Retinal Dystrophy: Documentation requirements were added for the genetically confirmed diagnosis of biallelic RPE65 mutation-associated retinal dystrophy and also to establish that the patient is not receiving retreatment of eye(s) previously treated with Luxturna.	09/15/2021
Selected Revision	Biallelic Human Retinal Pigment Epithelial 65 kDa Protein (RPE65) Mutation-Associated Retinal Dystrophy: Documentation requirements were added such that all of the criteria now require documentation.	10/20/2021
Annual Revision	No criteria changes.	02/23/2022